Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML Finance June 1, 2025 Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with…
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Finance June 1, 2025 Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American…
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology Finance June 1, 2025 Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology Taiho Oncology…
Karyopharm Therapeutics' SWOT analysis: oncology firm's stock faces pivotal year Finance May 25, 2025 Karyopharm Therapeutics' SWOT analysis: oncology firm's stock faces pivotal year Karyopharm Therapeutics' SWOT analysis: oncology firm's stock faces pivotal year…
Exelixis's SWOT analysis: stock poised for growth amid oncology pipeline progress Finance May 25, 2025 Exelixis's SWOT analysis: stock poised for growth amid oncology pipeline progress Exelixis's SWOT analysis: stock poised for growth amid oncology…
